Amylase: in the clinical trial subset of 1,008 patients, asymptomatic increases in serum amylase levels greater than 1.5 times the upper limit of normal were seen in 10% of patients treated with efavirenz and 6% of patients treated with control regimens.
Amülaas: kliinilise uuringu alarühma 1008 patsiendi hulgast leiti asümptomaatilist seerumi amülaasi kontsentratsiooni suurenemist rohkem kui 1, 5 korda üle normi ülemise piirväärtuse 10% patsientidest, keda raviti efavirensiga ja 6% - l kontrollrühma patsientidest.